Defining Targets for Continuous Glucose Monitoring After Total Pancreatectomy With Islet Autotransplantation
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70202 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, 2025. Verfasst von Zaynab Somani und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Minnesota Medical School, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Pancreatectomy, Islets of Langerhans Transplantation, Blood Glucose, Blood Glucose Self-Monitoring. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Introduction
Targets for continuous glucose monitoring (CGM) are well established for type 1 and type 2 diabetes. In total pancreatectomy with islet autotransplantation (TPIAT), stricter glycemic targets are needed to avoid metabolic stress on transplanted islets, but no guidelines exist for CGM targets.
Methods
We aimed to determine CGM targets for TPIAT clinical management by associating CGM metrics with goal hemoglobin A1c (HbA1c) ≤ 6.5%. Targets for time in range (TIR) 70–140, TIR 70–180, mean CGM glucose, and time in hyperglycemia (>140, >180, >250 mg/dL) were chosen to give good sensitivity and specificity for identifying HbA1c ≤6.5%.
Results
We included 256 pairs of 14‐day CGM metrics with a concurrent HbA1c value ( n = 82 patients, age 35 [IQR 19–46] years at surgery, 70% female) who were ≥0.5 years post TPIAT (median 4.1 years) and wearing Dexcom G6. Most patients had more than one HbA1c and corresponding CGM available (median 2 [IQR 1–4] per patient).
Conclusion
We found that TIR 70–140 ≥ 50% and TIR 70–180 mg/dL ≥ 75% may be reasonable minimum targets for patients and providers using CGM data to manage diabetes long‐term after TPIAT. Failure to meet these targets should prompt starting or adjusting insulin therapy, especially if hypoglycemia is not a concern.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Minnesota Medical School, Minneapolis, Minnesota, USA.
- Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
- Division of Transplantation, Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
- Division of Critical Care & Acute Care Surgery, Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
- Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
- Division of Endocrinology, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
ORCID-Profile: Zaynab Somani, James S Hodges, Srinath Chinnakotla, Karthik Ramanathan, Gregory J Beilman, Melena D Bellin
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Somani, Z., Hodges, J. S., Chinnakotla, S., Martin, D., Ramanathan, K., Beilman, G. J., & Bellin, M. D. (2025). Defining Targets for Continuous Glucose Monitoring After Total Pancreatectomy With Islet Autotransplantation. Clinical Transplantation. https://doi.org/10.1111/ctr.70202
Vancouver
Somani Z, Hodges JS, Chinnakotla S, Martin D, Ramanathan K, Beilman GJ, et al. Defining Targets for Continuous Glucose Monitoring After Total Pancreatectomy With Islet Autotransplantation. Clinical Transplantation. 2025. doi:10.1111/ctr.70202
BibTeX
@article{Somani2025,
author = {Somani, Zaynab and Hodges, James S and Chinnakotla, Srinath and Martin, David and Ramanathan, Karthik and Beilman, Gregory J and Bellin, Melena D},
title = {Defining Targets for Continuous Glucose Monitoring After Total Pancreatectomy With Islet Autotransplantation},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70202}
}
EUVIMED